NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-169-2016-0-DE-08 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS DE EP 17 808 241.8 Issued
NCI E-169-2016-0-FR-10 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS FR EP 17 808 241.8 Issued
NCATS E-096-2018-0-CN-05 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine CN National Stage 2019800423897 Issued
NCATS E-096-2018-0-AU-03 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine AU National Stage 2019282560 Issued
NCATS E-096-2018-0-ES-01 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine ES EP 19732189.6 Issued
NCATS E-096-2018-0-EP-06 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine EP National Stage 19732189.6 Issued
NCATS E-096-2018-0-IT-01 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine IT EP 19732189.6 Issued
NCATS E-096-2018-0-GB-01 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine GB EP 19732189.6 Issued
NCATS E-096-2018-0-DE-01 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine DE EP 19732189.6 Issued
NCATS E-096-2018-0-FR-01 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine FR EP 19732189.6 Issued
NCATS E-096-2018-0-PCT-02 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine PCT PCT PCT/US2019/035360 Expired
NCATS E-096-2018-0-JP-07 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine JP National Stage 2020-567577 Pending
NCATS E-096-2018-0-CA-04 Process For The Synthesis And Purification Of (2R,6R)-hydroxynorketamine CA National Stage 3102387 Pending
NICHD E-039-2016-1-US-06 TREATMENT OF HORMONAL DISORDERS OF GROWTH US CON 16/430,079 Abandoned
NCATS E-091-2016-0-CN-04 COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE CN National Stage 201780074074.1 Pending
NIAID E-174-2017-1-MX-05 Protection Of Calves By A Prefusion-stabillze Bovine RSV Vaccine MX National Stage MX/a/2019/006349 Pending
NIBIB E-005-2012-3-CN-08 MULTI-FOCAL STRUCTURED ILLUMINATION MICROSCOPY SYSTEMS AND METHODS CN National Stage 201880004664.1 Issued
NIAID E-135-2010-0-US-08 GENETICALLY STABLE LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE AND ITS PRODUCTION US CON 16/425,725 10980872 Issued PDF
NEI E-164-2014-0-US-06 METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS US DIV 16/423,962 1142-12-19 Issued PDF
NIAID E-145-2011-0-IN-15 Plasmodial Surface Anion Channel Inhibitors For The Treatment Of Prevention Of Malaria IN DIV 201948020664 Issued
NCATS E-190-2016-0-US-08 1 H-PYRAZOL-1-YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF US National Stage 16/313,727 10954228 Issued PDF
NIAID E-191-2018-0-PCT-02 Improved Methods Of Manufacturing Peptide-Based Vaccines PCT PCT PCT/US2019/033612 Expired
NIAID E-191-2018-0-CN-06 Improved Methods Of Manufacturing Peptide-Based Vaccines CN National Stage 201980049152.1 Pending
NIAID E-191-2018-0-EP-07 Improved Methods Of Manufacturing Peptide-Based Vaccines EP National Stage 19734178.7 Pending
NIAID E-191-2018-0-IN-08 Improved Methods Of Manufacturing Peptide-Based Vaccines IN National Stage 202017055861 Pending
NIAID E-191-2018-0-AU-04 Improved Methods Of Manufacturing Peptide-Based Vaccines AU National Stage 2019272844 Pending
NIAID E-191-2018-0-CA-05 Improved Methods Of Manufacturing Peptide-Based Vaccines CA National Stage 3104729 Pending
NCATS E-230-2016-2-US-02 Tools To Develop A Therapy For The Treatment Of Zellweger Spectrum Disorder US CON 16/417,167 11065247 Issued PDF
NHGRI E-217-2007-0-US-17 N-ACETYL MANNOSAMMINE AS A THERAPEUTIC AGENT US CON 16/417,488 10953026 Issued PDF
NHLBI E-219-2018-2-PCT-01 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging PCT PCT COMB PCT/IB2019/054112 Expired
NHLBI E-219-2018-2-EP-04 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging EP National Stage 19803953.9 Abandoned
NHLBI E-219-2018-2-JP-06 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging JP National Stage 2021-514658 Pending
NHLBI E-219-2018-2-KR-05 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging KR National Stage 10-2020-7036354 Pending
NHLBI E-219-2018-2-CA-02 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging CA National Stage 3085303 Pending
NIAID E-086-2018-3-US-02 Zika Viral Antigen Constructs US National Stage 16/461,503 11780885 Issued PDF
NCI E-150-2018-0-PCT-02 CATALYTICALLY HYPERACTIVE VARIANTS OF HUMAN APOBEC3G PROTEIN PCT PCT PCT/US2019/032720 Expired
NIA E-279-2013-0-US-04 METHODS FOR SELECTIVE INHIBITION OF PLURIPOTENT STEM CELLS US DIV 16/414,025 Pending
NCATS E-114-2018-0-PCT-02 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS PCT PCT PCT/US2019/32461 Expired
NCATS E-114-2018-0-CA-04 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS CA National Stage 3100211 Pending
NCI E-040-2012-0-EA-31 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen EA DIV 201990959 Issued
NCI E-040-2012-0-KZ-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen KZ EA 201990959 Issued
NCI E-040-2012-0-KG-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen KG EA 201990959 Issued
NCI E-040-2012-0-AZ-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen AZ EA 201990959 Issued
NCI E-040-2012-0-AM-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen AM EA 201990959 Issued
NCI E-040-2012-0-BY-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen BY EA 201990959 Issued
NCI E-040-2012-0-RU-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen RU EA 201990959 Issued
NCI E-040-2012-0-TJ-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen TJ EA 201990959 Issued
NCI E-040-2012-0-TM-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen TM EA 201990959 Issued
NCI E-121-2013-0-US-05 METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER US CON 16/412,003 11555818 Issued PDF
NLM E-107-2010-2-US-26 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/411,998 10793899 Issued PDF